Kindred Biosciences, Inc.
KIN
KIN was delisted on the 27th of August, 2021.
67 hedge funds and large institutions have $148M invested in Kindred Biosciences, Inc. in 2017 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 28 increasing their positions, 16 reducing their positions, and 7 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 16
29% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 7
2% more funds holding
Funds holding: 66 → 67 (+1)
2% more capital invested
Capital invested by funds: $145M → $148M (+$3.08M)
99% less call options, than puts
Call options by funds: $1K | Put options by funds: $82K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GAI
General American Investors
New York
|
+$5M |
| 2 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$4.5M |
| 3 |
AI
Ariel Investments
Chicago,
Illinois
|
+$2.84M |
| 4 |
PGC
Pacific Grove Capital
San Francisco,
California
|
+$1.41M |
| 5 |
BlackRock
New York
|
+$963K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Cannell Capital
Alta,
Wyoming
|
-$1.38M |
| 2 |
Citigroup
New York
|
-$616K |
| 3 |
GIP
Granite Investment Partners
El Segundo,
California
|
-$361K |
| 4 |
Millennium Management
New York
|
-$289K |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$170K |
KIN Hedge Fund Activity: Q3 2017 in Review
67 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Kindred Biosciences, Inc. (KIN) for Q3 2017, worth a combined $148M — up 2.1% from $145M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new KIN positions and 7 closed out — a net gain of 2 holders — while 28 added to existing stakes and 16 trimmed.
The largest buyer was General American Investors, opening a new position worth an estimated $5M. The largest seller was Cannell Capital, cutting an estimated $1.38M.
- 67 institutional investors held Kindred Biosciences, Inc. (KIN) as of Q3 2017, up from 66 in Q2 2017.
- Funds reported $148M of Kindred Biosciences, Inc. stock for Q3 2017, up 2.1% quarter-over-quarter.
- 9 funds opened new Kindred Biosciences, Inc. positions in Q3 2017 and 7 closed out, a net change of +2 holders.
- The largest Kindred Biosciences, Inc. buyer in Q3 2017 was General American Investors, an estimated $5M added.
- The largest Kindred Biosciences, Inc. seller in Q3 2017 was Cannell Capital, an estimated $1.38M sold.
Based on aggregated 13F filings for Q3 2017.